CANTANHEDE, Portugal - Tilray (NASDAQ:TLRY) Brands, Inc. (NASDAQ:TLRY; TSX:TLRY), a global leader in the cannabis industry, has achieved a significant milestone in Portugal with the approval of its first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20. This development marks a notable advancement in the availability of medical cannabis products for patients in Portugal.
The approval, granted on March 11, 2024, allows Tilray Medical to provide a new form of therapy to Portuguese patients with certain medical conditions. The Tilray Oral Solution THC 5 CBD 20 is the first medical cannabis extract to be sanctioned in the country, expanding the company's existing portfolio of EU-GMP certified medicinal cannabis products.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, expressed the company's commitment to medical cannabis research and patient accessibility. "
This is a monumental step forward for patient care in Portugal," Faltischek said. "With the approval of our first medical cannabis extract, we are proud to be at the forefront of medical cannabis research and accessibility and continue to demonstrate our commitment to providing innovative, safe, and effective therapeutic options to patients."
The newly approved medical cannabis extract is anticipated to be available in late spring, enhancing therapeutic choices for patients across Portugal. Tilray Medical, with operations in over 20 countries, remains dedicated to supporting patient care worldwide through quality products accessible via healthcare practitioners.
Tilray Medical has been a pioneer in the medical cannabis industry, from being one of the first companies to receive approval as a licensed producer in Canada to establishing the first GMP-certified cannabis production facilities in Europe. It has grown into one of the largest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments on five continents.
The information in this article is based on a press release statement from Tilray Brands, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.